MDxHealth Appoints New Scientific Advisory Board
(Thomson Reuters ONE) -
DURHAM, NC, and LIEGE, BELGIUM - March 24th, 2011 - MDxHealth SA (NYSE Euronext:
MDXH), a leading molecular diagnostics company in the field of personalized
cancer treatment, today announced that it has appointed a high profile
Scientific Advisory Board (SAB) to support the Company's management in their new
strategy. The SAB members will assist management in the development of current
pipeline programs, as well as advise on new directions for the application of
MDxHealth's technology platform.
"Each person joining our new Scientific Advisory Board is a pioneer in cancer
molecular diagnostics, including prostate cancer, an indication where MDxHealth
is particularly strong," said Dr. Jan Groen, Chief Executive Officer of
MDxHealth. "Their long-standing experience and extensive networks will provide
us with invaluable hands-on strategic support in the development of our existing
programs and help us open up new avenues for the application of our DNA
methylation platform."
The Scientific Advisory Board will consist of:
Jonathan I. Epstein, MD
Dr. Epstein is the Reinhard Professor of Urologic Pathology, Professor,
Departments of Pathology, Urology and Oncology and Director of Surgical
Pathology, Department of Pathology at the Johns Hopkins University School of
Medicine. He is one of the acknowledged world experts in the field of urologic
pathology. He is responsible for the largest genitourinary pathology fellowship
program in the world, with four fellows per year. As Director of Genitourinary
Pathology Consult Service he oversees approximately 16,000 genitourinary
pathology consults received per year. His areas of particular interest include
prostatic intraepithelial neoplasia; diagnosis of limited adenocarcinoma on
needle biopsy; prediction of prostate cancer prognosis, and unusual subtypes of
bladder carcinoma.
James G. Herman, MD
Dr. Herman is Professor of Oncology-Cancer Biology at the Oncology Center at
Johns Hopkins Medical Institutions. His laboratory pioneered methylation-
specific-PCR technology and continues to focus on epigenetic changes that
pertain to development and progression of human cancers. Dr. Herman's
publications have significantly advanced the fields of epigenetics and its
impact on human cancer. Dr. Herman also has a clinical position in the Johns
Hopkins Cancer Center. His applied research in the areas of pharmacogenomics
and genomic instability have led to the development of diagnostic tests that
could vastly improve clinical outcomes in patients with several types of cancer.
Gerrit A. Meijer, MD, PhD
Dr. Meijer is Professor of Pathology and chair of the Department of Pathology at
the Free University Medical Center, in Amsterdam The Netherlands, co-chair of
the Genomics Center, leader of the Master Oncology program, director of the
Oncology Graduate School Amsterdam, and editor-in-chief of Cellular Oncology.
Dr. Meijer is a pathologist with a special interest in cancer research, focusing
on the gastrointestinal tract. He leads a research group that focuses on
translational research in colorectal and gastric cancers. Current research
topics include genomic and proteomic tumor profiling for stratifying patients
for individually tailored therapies. Furthermore, genomic and proteomic
profiling of pre-malignant lesions is used for identification and validation of
biomarkers for early cancer detection.
Eric M. Wallen, MD
Dr. Wallen is Associate Professor of Surgery in the Division of Urology at the
University of North Carolina Medical Center at Chapel Hill, and focuses
primarily on prostate cancer. Prior to 2003 he was Assistant Professor of
Urology at Dartmouth Medical School in New Hampshire. Dr. Wallen obtained his
Medical Doctor (MD) degree from the University of California, Los Angeles,
School of Medicine and a Bachelor of Arts degree from Yale University in New
Haven, Connecticut. He did his specialty training (internship and residency) in
General Surgery and Urology at Stanford University Medical Center, Stanford,
California. He is American Board Certified in the field of urology. Dr. Wallen
is an expert in the cutting-edge technique of robotic, nerve-sparing
prostatectomy surgery. Dr. Wallen has published widely in peer-reviewed journals
and authored numerous medical book chapters. His in-depth knowledge of the
diverse clinical settings of prostate cancer is gained from current patient
management as well as involvement in cutting-edge research to improve disease
diagnosis, treatment and prognosis.
About MDxHealth
MDxHealth is a leading molecular diagnostics company that develops and
commercializes oncology-based molecular diagnostic testing for personalized
medicine. The company's tests are based on proprietary gene methylation
technology and assist physicians with the diagnosis of cancer, prognosis of
recurrence risk, and prediction of response to a specific therapy. MDxHealth
collaborates with leading cancer research center such as Johns Hopkins
University and Memorial Sloan Kettering, and major European academic medical
centers. The company has a number of commercial and collaborative partnerships
with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche,
Merck Serono, Pfizer, and other industry leaders. More information can be found
on the Company website:www.mdxhealth.com or on twitter at the following address
: www.twitter.com/mdxhealth.
For more information:
Dr. Jan Groen, CEO Hans Herklots
MDxHealth Capricorn One
+32 4 364 20 70 +41 79 598 7149
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the Company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation
2011-03-24 New SAB ENG:
http://hugin.info/137314/R/1499319/434857.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MdxHealth via Thomson Reuters ONE
[HUG#1499319]
Unternehmensinformation / Kurzprofil:
Datum: 24.03.2011 - 08:00 Uhr
Sprache: Deutsch
News-ID 52746
Anzahl Zeichen: 8057
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 236 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MDxHealth Appoints New Scientific Advisory Board"
steht unter der journalistisch-redaktionellen Verantwortung von
MdxHealth (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
